Eli Lilly to add $4.1B U.S. sales from obesity drug Zepbound


Eli Lilly and Company

hapabapa/iStock Editorial via Getty Images

Sales from Eli Lilly’s (NYSE:LLY) newly approved weight loss medication, Zepbound, could reach $4.1B by 2031 in the U.S., a recent report from data analytics firm GlobalData indicates.

According to the report, that is about half the level of rival Novo

Source link

Leave A Reply

Your email address will not be published.